GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Exscientia PLC (NAS:EXAI) » Definitions » EV-to-FCF

Exscientia (Exscientia) EV-to-FCF : -3.02 (As of Jun. 02, 2024)


View and export this data going back to 2021. Start your Free Trial

What is Exscientia EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Exscientia's Enterprise Value is $465.17 Mil. Exscientia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 was $-153.97 Mil. Therefore, Exscientia's EV-to-FCF for today is -3.02.

The historical rank and industry rank for Exscientia's EV-to-FCF or its related term are showing as below:

EXAI' s EV-to-FCF Range Over the Past 10 Years
Min: -95.72   Med: -1.61   Max: 947.42
Current: -2.65

During the past 5 years, the highest EV-to-FCF of Exscientia was 947.42. The lowest was -95.72. And the median was -1.61.

EXAI's EV-to-FCF is ranked worse than
100% of 377 companies
in the Biotechnology industry
Industry Median: 8.21 vs EXAI: -2.65

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-06-02), Exscientia's stock price is $5.28. Exscientia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $-1.308. Therefore, Exscientia's PE Ratio for today is At Loss.


Exscientia EV-to-FCF Historical Data

The historical data trend for Exscientia's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Exscientia EV-to-FCF Chart

Exscientia Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-FCF
- - -78.06 -0.01 -2.21

Exscientia Quarterly Data
Dec19 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.78 -0.60 -0.46 -2.21 -3.32

Competitive Comparison of Exscientia's EV-to-FCF

For the Biotechnology subindustry, Exscientia's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Exscientia's EV-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Exscientia's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Exscientia's EV-to-FCF falls into.



Exscientia EV-to-FCF Calculation

Exscientia's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=465.174/-153.971
=-3.02

Exscientia's current Enterprise Value is $465.17 Mil.
Exscientia's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-153.97 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Exscientia  (NAS:EXAI) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Exscientia's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.28/-1.308
=At Loss

Exscientia's share price for today is $5.28.
Exscientia's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1.308.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Exscientia EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Exscientia's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Exscientia (Exscientia) Business Description

Traded in Other Exchanges
Address
Oxford Science Park, The Schrodinger Building, Oxford, GBR, OX4 4GE
Exscientia PLC is engaged in the application of artificial intelligence (AI) and machine learning (ML) to the discovery and design of novel therapeutic compounds. The company's technology platform combines human and computational capabilities to accelerate the process of designing novel, safe and efficacious compounds for clinical testing in humans. The company is focused on the discovery and development of small-molecule drug candidates.